TCM
TCRX icon

Tang Capital Management’s TScan Therapeutics TCRX Stock Holding History

Tang Capital Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-46,131
Closed -$46.1K – 73
2025
Q4 		$46.1K Sell
46,131
-553,869
-92% -$802K ﹤0.01% 74
2025
Q3 		$1.09M Hold
600,000
– – 0.04% 152
2025
Q2 		$870K Hold
600,000
– – 0.04% 164
2025
Q1 		$828K Buy
600,000
+482,153
+409% +$1.04M 0.05% 165
2024
Q4 		$358K Buy
+117,847
New +$534K 0.02% 175
2023
Q1 		– Sell
-514,655
Closed -$798K – 120
2022
Q4 		$798K Sell
514,655
-43,260
-8% -$106K 0.12% 72
2022
Q3 		$1.7M Sell
557,915
-189,885
-25% -$622K 0.21% 74
2022
Q2 		$2.35M Buy
747,800
+547,800
+274% +$1.5M 0.36% 48
2022
Q1 		$560K Buy
+200,000
New +$865K 0.11% 53

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Tang Capital Management's TCRX Position: Q1 2026 in Review

Tang Capital Management sold out of TScan Therapeutics (TCRX) in Q1 2026, closing a stake of 46,131 shares — an estimated $46.1K sold.

Tang Capital Management first reported a position in TCRX in Q1 2022 and held it in 9 quarters. The position peaked at $2.35M in Q2 2022. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Tang Capital Management reported no remaining TScan Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Tang Capital Management sold 46,131 TScan Therapeutics shares in Q1 2026, an estimated $46.1K.
  • Tang Capital Management first reported a position in TScan Therapeutics in Q1 2022 and held it in 9 quarters.
  • Tang Capital Management's TScan Therapeutics position peaked at $2.35M in Q2 2022.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Tang Capital Management's 13F filing for Q1 2026, filed 15 May 2026.